This, in turn, is leading to a rise in their adoption rates
This regulatory acknowledgment validates concerns that manufacturers should have disclosed this risk earlier, given the conditions catastrophic and permanent nature
de Oliveira AlmeidaGNienktterTFBalieiroCCAPasqualottoECintraJBCarvalhoHCPet alCardiovascular benefits of GLP-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials
The question is no longer if youre in the health business
GLP-1 drugs like Ozempic and Wegovy are groundbreaking treatments for type 2 diabetes and obesity
Alternatively, the manufacturer advises switching to a non-oral contraceptive, such as an IUD, patch, or implant (7,8,14)